CGEN - コンピュジェン (Compugen Ltd.) コンピュジェン

 CGENのチャート


 CGENの企業情報

symbol CGEN
会社名 Compugen Ltd (コンピュジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンピュジェン(Compugen Ltd.)は治療薬の発見会社で、免疫学と腫瘍学分野での満たされていない重要なニーズに対応する治療用タンパク質及びモノクローナル抗体を中心とする。同社は主に発見された製品候補のさらなる開発・商業化及び各種形態の研究・発見契約を含む提携を行う。同社のプログラムパイプラインは検証から前臨床試験に至るまで様々な段階における30種類以上の治療薬候補で構成される。パイプラインプログラムの下で、新たに発見された分子はシリコン内での予測と選択の直後での実験的評価を開始する時にプログラムに入る。パイプラインプログラムは追加の18ヶ月間以下の特定分子向けの様々な前臨床活動が続く動物疾患モデルや重複実験を含む生体内及び生体内の実験的検証で構成される。   コンピュジェンはイスラエルの製薬会社。モノクロ―ナル抗体および腫瘍学および免疫学の分野の治療用タンパク質に焦点を当て薬剤の開発を行う。同社は、伝統的な実験に基づく薬物候補の発見とは異なり、コンピュ―タによって独自の科学的理解および予測プラットフォ―ム、アルゴリズム、機械学習システムを利用し、予測し製品候補の開発を行う。本社はテレアビブ。   Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
本社所在地 Azrieli Center 26 Harokmim Street Building D Holon 5885849 ISR
代表者氏名 Paul Jai Sekhri ポール・ジャイ・セクフリ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-765-8585
設立年月日 34001
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 101人
url www.cgen.com
nasdaq_url https://www.nasdaq.com/symbol/cgen
adr_tso
EBITDA EBITDA(百万ドル) -29.58400
終値(lastsale) 3.36
時価総額(marketcap) 192182017.44
時価総額 時価総額(百万ドル) 194.16020
売上高 売上高(百万ドル) 10.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151.70420
当期純利益 当期純利益(百万ドル) -29.27000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Compugen Ltd. (USA) revenues increased from $0K to $10M. Net loss decreased 44% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.35 to -$0.19.

 CGENのテクニカル分析


 CGENのニュース

   Compugen''s bispecific antibody derived from COM902 to enter clinical development  2021/08/19 11:56:31 Seeking Alpha
   Compugen Ltd (CGEN) Q2 2021 Earnings Call Transcript  2021/07/29 01:02:04 The Motley Fool
CGEN earnings call for the period ending June 30, 2021.
   Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript  2021/07/28 19:10:04 Seeking Alpha
   Compugen posts Q2 results, provides cash position update  2021/07/28 14:07:15 Seeking Alpha
   Big Pharma is betting billions on the next cancer breakthrough. Here are the 13 drug companies leading the way.  2021/07/20 11:30:00 Business Insider
Summary List Placement Big Pharma is betting billions on a new class of cancer treatments. The hope is that the new approach will expand the benefits of immunotherapy to more patients. The first immunotherapies were approved a decade ago in 2011 . These drugs, which harness the body''s own immune system to fight cancer, have delivered transformative benefits to some patients. But the success has been limited to a fraction of cancer patients . In the years since, drug companies have tested thousands of treatment combinations to further that progress. Drugs targeting a protein called TIGIT have caught the industry''s attention, with some of the world''s largest drug companies now rushing into the space. Researchers hope TIGIT-targeted drugs can improve existing treatments when used with other immunotherapies. The hope is these combinations will help more patients and provide longer-lasting benefits in fighting off cancer, ultimately expanding the utility of cancer immunotherapy. The first clinical data testing a TIGIT-targeting drug with an existing immunotherapy found that more lung cancer patients responded than those who had received the existing immunotherapy alone.
   Dosing underway in Compugen''s Phase 1 COM902 combo study in advanced malignancies  2021/07/15 12:00:46 Seeking Alpha
   South and Central America Drug Modelling Software Market Will Generate Record Revenue by 2027 Covid-19 Analysis | Compugen Ltd., Biognos AB, Dassault Systèmes, Acellera  2021/07/01 08:48:39 Industry Today
The South & Central America drug modelling software market is expected to reach US$ 606.80 million by 2027 from US$ 359.46 million in 2019. The market is anticipated to grow at a CAGR of 7.1% during 20192027. Posted via Industry Today. Follow us on Twitter @IndustryToday
   Compugen (CGEN) Presents At TIGIT Pathway:Deep Dive in Cancer Immunotherapy Targets - Slideshow  2021/06/30 19:52:55 Seeking Alpha
   Dosing underway in Compugen''s COM701/Opdivo Phase 1b cohort expansion study  2021/06/30 13:10:30 Seeking Alpha
   Other news to note for June 29, 2021  2021/06/29 15:00:00 BioWorld
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acrivon, Amgen, Antios, Applied Biomath, APR, Arbutus, Astrazeneca, Baymedica, Brigham and Women''s Hospital, Cannex, Carmot, Cell and Gene Therapy Catapult, Compugen, Curie Institute, Defence, Diurnal, Elevatebio, E r-Kim, Etherna, Ichnos, Inmed, Innovent, Ixaka, KBI, Lilly, Mosaic Biosciences, Mosaic Immunoengineering, Ocular, Paratek, PYC, Q-State, Quantoom, Relief, Selexis, Simcere, Somalogic, Synaffix, Vivoryon.
   South and Central America Drug Modelling Software Market Will Generate Record Revenue by 2027 Covid-19 Analysis | Compugen Ltd., Biognos AB, Dassault Systèmes, Acellera  2021/07/01 08:48:39 Industry Today
The South & Central America drug modelling software market is expected to reach US$ 606.80 million by 2027 from US$ 359.46 million in 2019. The market is anticipated to grow at a CAGR of 7.1% during 20192027. Posted via Industry Today. Follow us on Twitter @IndustryToday
   Compugen (CGEN) Presents At TIGIT Pathway:Deep Dive in Cancer Immunotherapy Targets - Slideshow  2021/06/30 19:52:55 Seeking Alpha
   Dosing underway in Compugen''s COM701/Opdivo Phase 1b cohort expansion study  2021/06/30 13:10:30 Seeking Alpha
   Other news to note for June 29, 2021  2021/06/29 15:00:00 BioWorld
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acrivon, Amgen, Antios, Applied Biomath, APR, Arbutus, Astrazeneca, Baymedica, Brigham and Women''s Hospital, Cannex, Carmot, Cell and Gene Therapy Catapult, Compugen, Curie Institute, Defence, Diurnal, Elevatebio, E r-Kim, Etherna, Ichnos, Inmed, Innovent, Ixaka, KBI, Lilly, Mosaic Biosciences, Mosaic Immunoengineering, Ocular, Paratek, PYC, Q-State, Quantoom, Relief, Selexis, Simcere, Somalogic, Synaffix, Vivoryon.
   Biosimulation Market 2021 Analysis with Research Report - Biovia, Certara, L.P., Compugen Inc., Genedata, In Silico Biosciences, Inc  2021/06/24 17:17:13 OpenPR
Global Biosimulation Market Growth, Trends, And Forecast (2021 2025) The report presents an in-depth assessment of the Global Biosimulation Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンピュジェン CGEN Compugen Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)